MediWound Ltd. has recently reported favorable results from comparative analyses of their leading product, EscharEx, intending to treat chronic wounds, with SANTYL ointment, which the FDA approves for treating chronic dermal ulcers.
The secondary analysis from the Phase II ChronEx study revealed that EscharEx outperforms SANTYL in wound debridement, promoting granulation tissue, and speeding up wound closure in patients who have chronic venous leg ulcers.
This comparative analysis assessed the incidence rate and the time taken to complete debridement, full granulation, and wound closure in patients treated with EscharEx versus a subgroup of patients treated with SANTYL.
The previous Phase II ChronEx study results, which examined EscharEx's safety and effectiveness, showed that it was superior to the placebo and the non-surgical standard care in achieving complete debridement of non-viable tissue and promoting granulation tissue.
MediWound Ltd. intends to begin a Phase III study in the later part of this year.
